Table 2.

Fas/Fas ligand pathway polymorphisms associated (p <0.05) with acute kidney injury (AKI) susceptibility in Caucasian subjects from the Fluid and Catheter Treatment Trial

Gene	SNP	OR (95 % CI)a	P value	FDR-adjusted P value	MAF
NFKBIA	rs1050851	2.34 (1.58–3.46)	1.06 × 10−5	<0.003	0.18
NFKBIA	rs2233417	2.46 (1.61–3.76)	1.81 × 10−5	<0.003	0.15
CFLAR	rs12105811	0.51 (0.33–0.79)	0.002	0.18	0.25
NFKBIA	rs7157810	1.70 (1.15–2.51)	0.007	0.50	0.18
FASLG	rs5030772	1.80 (1.16–2.79)	0.007	0.41	0.11
BCL2L1	rs1484994	0.63 (0.44–0.91)	0.011	0.54	0.35
BCL2L1	rs6060621	0.65 (0.45–0.92)	0.015	0.60	0.35
TIRAP	rs1786697	0.60 (0.39–0.92)	0.017	0.60	0.23
RELA	rs10896027	1.49 (1.06–2.11)	0.022	0.69	0.34
MAP3K1	rs33330	0.64 (0.43–0.95)	0.024	0.69	0.34
NFKBIA	rs8904	0.67 (0.47–0.96)	0.027	0.69	0.41
CFLAR	rs4482462	0.65 (0.44–0.96)	0.028	0.67	0.27
NFKBIA	rs696	0.68 (0.48–0.96)	0.029	0.63	0.41
DAXX	rs2239839	1.50 (1.03–2.18)	0.032	0.65	0.26
CFLAR	rs6728771	0.66 (0.45–0.97)	0.034	0.64	0.27
MAP3K5	rs911179	0.70 (0.50–0.98)	0.037	0.66	0.48
CASP9	rs1862710	0.71 (0.51–0.99)	0.041	0.68	0.49
MYD88	rs6853	0.61 (0.38–1.00)	0.047	0.76	0.16
BCL2L1	rs6058381	0.53 (0.28–1.02)	0.048	0.72	0.09
TLR6	rs3821985	0.71 (0.50–1.00)	0.049	0.70	0.38
CFLAR	rs7583529	0.68 (0.46–1.00)	0.0497	0.67	0.26
MAP3K5	rs1570054	0.71 (0.50–1.00)	0.0498	0.64	0.40

^aRisk of AKI (stage 1 or above) with each additional copy of the minor allele. SNP single nucleotide polymorphism, OR odds ratio, FDR false discovery rate, MAF minor allele frequency